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T cell development is a highly regulated physiological process 
through which T cells acquire competence for antigen recog-
nition; those recognizing self-antigens with high affinity are 
physically deleted before migrating to peripheral lymphoid 
organs (Palmer, 2003). Alterations of this process lead to both 
defective immune responses to foreign antigens and to auto-
immunity. Even though the avidity of the TCR for self-pep-
tide–MHC complexes is a key factor in determining the fate 
of developing thymocytes and the outcome of peripheral 
T cell immune responses, concomitant signals provided by 
other lymphocyte surface receptors are known to influence 
this process by increasing or reducing the threshold for TCR 
signaling (Palmer, 2003). One such receptor is CD5 (Soldevila 
et al., 2011), and this could be also the case for the related 
molecule CD6, as they are highly homologous receptors en-
coded by contiguous genes most likely arising from duplica-
tion of a common ancestor. Indeed, CD5 associates with the 
antigen-specific receptor complex and negatively modulates 
its signaling. In turn, the expression levels of CD5 on T cells 
reflects the strength of TCR signaling, which reciprocally 
tunes the threshold of the response.
CD6 is a 105–130-kD surface glycoprotein expressed 
on all T cells from early stages of their development, but also 
on some B and NK subsets, BM precursors, and brain areas 
(Santos et al., 2016). The extracellular domain of CD6 com-
prises three scavenger receptor cysteine-rich extracellular do-
mains, the most membrane-proximal of which (D3) interacts 
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with the N-terminal immunoglobulin domain of CD166/
ALC AM (activated leukocyte cell adhesion molecule), a 
broadly expressed cell adhesion molecule (Santos et al., 2016). 
The structure of CD6 and the binding region of ALC AM 
have recently been resolved (Chappell et al., 2015). In vitro 
assays revealed that this interaction is critical for optimal T cell 
activation and proliferative responses (Gimferrer et al., 2004; 
Hassan et al., 2004; Zimmerman et al., 2006). Indeed, when 
co-cross-linked with anti-CD3 mAb, CD6 increased pro-
liferation, intracellular Ca2+ levels, and activation of MAPK 
in human T cells (Santos et al., 2016). The CD6 cytoplas-
mic region is devoid of intrinsic catalytic activity, but harbors 
consensus motifs for phosphorylation and association with 
signal-transducing effectors. Accordingly, CD6 holds two 
constitutively phosphorylated Ser clusters needed for proper 
MAPK activation (Bonet et al., 2013), and nine Tyr residues 
that may be phosphorylated upon TCR activation and serve 
as docking sites for downstream signaling effectors, such as 
Syntenin-1 and SLP-76 (Gimferrer et al., 2005; Hassan et al., 
2006). The latter has been recently confirmed by quantitative 
proteomic analysis of primary mouse T cells (Roncagalli et 
al., 2014), showing that SLP-76 binds to CD6 in a ZAP-70–
dependent but LAT-independent manner, and placing CD6 
as a signaling molecule that contributes to the diversifica-
tion of TCR signals. In this regard, CD6 is well positioned to 
modulate the TCR signaling as it physically associates with 
the TCR complex and co-localizes with it at the center of the 
immunological synapse during APC–T cell contacts (Gim-
ferrer et al., 2004; Zimmerman et al., 2006). However, the be-
lief that CD6 behaves as a co-stimulatory molecule has been 
recently challenged by in vitro data showing that it may also 
act as a negative modulator of TCR signaling (Hassan et al., 
2006; Oliveira et al., 2012).
Besides its role in T cell activation, a single study has 
also shown CD6 to be involved in thymocyte survival and 
selection in mice and humans (Singer et al., 2002). This study 
showed that CD6 surface expression levels increase when 
double-positive (DP) thymocytes are selected to become 
single-positive (SP) cells, and that such increases correlate 
with both expression of the selection marker CD69 and 
resistance to apoptosis.
All the aforementioned in vitro evidences support a 
putative involvement for CD6 in the modulation of thy-
mocyte selection and T lymphocyte activation (Santos et al., 
2016). However, the lack of proper animal models has hin-
dered further understanding of its in vivo role during relevant 
physiological processes. This report provides the first analysis 
on the in vivo consequences of CD6 deficiency on T cell 
development, homeostasis, and activation. Our results show 
that CD6 modulates the threshold for negative selection in 
thymus and influences the generation and/or function of pe-
ripheral effector/memory and regulatory (T reg) T cells. The 
functional defects associated with CD6 deficiency also result 
in an exacerbated autoimmune response in a model of colla-
gen-induced arthritis (CIA).
RES ULTS AND DIS CUS SION
CD6 deficiency impacts normal T cell development
The role of CD6 in T cell development was assessed by gen-
erating CD6−/− C57BL/6N mice in which exons coding for 
the extracellular region of CD6 were deleted by homolo-
gous recombination (Fig.  1 A). Flow cytometry analysis of 
LN CD4+ and CD8+ T cells from CD6−/− mice showed a 
complete lack of CD6 surface expression as compared with 
CD6+/+ and CD6+/− littermates (Fig. 1 B). Analysis of thy-
mus from sex- and age-matched CD6−/− and CD6+/+ litter-
mates showed no significant differences in total cell numbers 
(Fig. 1 C, left). Although no differences were found in the 
frequency of NKT (CD161+CD3+) and γδ T cells (not de-
picted), as well as of DP or double-negative (DN) thymo-
cyte subsets, a significant decrease was observed for CD4+SP 
cells (Fig. 1 C, middle). A detailed analysis of CD8+SP cells 
showed a reduction in the frequency of mature CD8+SP 
(TCRβ+CD24−), together with an increase in immature 
CD8+SP (TCRβ−CD24+; Fig.  1  C, right). These findings 
suggest the involvement of CD6 in the final steps of thy-
mocyte selection. Consistent with that view, CD6 expression 
correlated with that of the positive selection marker CD69 
in DP thymocytes (Fig.  1  D). A similar situation has been 
documented for CD5, a negative modulator of TCR signal-
ing (Tarakhovsky et al., 1995) whose expression is develop-
mentally regulated in a TCR signal- and avidity-dependent 
manner (Azzam et al., 2001). A significant increase in the fre-
quency of DP cells undergoing selection (CD69+DP) and a 
concomitant reduction in recently selected CD69+CD4+SP 
and CD69+CD8+SP was found in CD6−/− mice as compared 
with CD6+/+ mice (Fig. 1 E). These results suggest that, rather 
than a defect in positive selection per se, CD6 deficiency 
triggers an increase in the negative selection of CD4+ and 
CD8+SP cells, the final product of the DP to SP transition.
CD6 deficiency impacts peripheral effector/memory and 
regulatory T cell compartments
Analysis of spleen and LN from CD6−/− mice revealed total 
cell numbers (Fig. 2 A, left) and percentage of T (both CD4+ 
and CD8+), B (CD19+; Fig. 2 A, right), γδT, NK, and NKT 
cells (not depicted) similar to those found in CD6+/+ litter-
mates. Surface levels of CD3, CD4, CD8, and CD45 from pe-
ripheral CD6−/− T cells were also similar to those of CD6+/+ 
cells (Fig. 2 B). However, a slightly reduced CD5 expression 
was observed on both CD4+ and CD8+ spleen T cells from 
CD6−/− mice compared with CD6+/+ littermates (Fig. 2 C). 
This was also true for thymocytes, from early to late matura-
tional stages (Fig. 2 C). The intriguing fact is that the analysis 
of CD5−/− mice revealed increased CD6 expression in both 
CD4+ and CD8+ spleen T cells but not thymocytes. These re-
ciprocal changes observed in both CD6−/− and CD5−/− mice 
suggest a functional cross-talk in the regulation of CD6 and 
CD5 surface expression that deserves further exploration.
Analysis of spleen and LN also revealed that CD6−/− 
mice present significantly increased percentages of effector/
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memory CD4+ (CD4+TEM and CD44hiCD62Llo) and cen-
tral memory CD8+ (CD8+TCM and CD44hiCD62Lhi) T cells 
(Fig. 2 D). Increased percentages of cells with T reg cell phe-
notype (CD4+CD25+FoxP3+) were also observed (Fig. 2 E). 
Interestingly, this increase could not be detected in the thy-
mus, suggesting that CD6 deficiency does not affect the gen-
eration of thymic T reg cells. Collectively, the data indicate 
that CD6 deficiency favors the expansion of antigen-expe-
rienced peripheral T cell subsets generated under high TCR 
signal strength conditions (Lanzavecchia and Sallusto, 2005).
Increased frequency of effector/memory T cells has 
been attributed to homeostatic proliferation, also known as 
lymphopenia-induced proliferation (Jameson, 2002). Such an 
increase could result from the decreased thymic output ob-
served in the absence of CD6 (Fig. 1 C). However, the lower 
BrdU incorporation observed in spleen and LN CD8+TCM 
and CD4+TEM cells from CD6−/− mice (Fig.  2  F) argued 
against the possibility of increased homeostatic proliferation. 
Instead, the previously reported role of CD6–ALC AM in-
teractions in optimizing T cell activation and proliferative 
responses (Gimferrer et al., 2004; Hassan et al., 2004; Zim-
merman et al., 2006) could feasibly account for the low in 
vivo proliferation observed.
T cell–intrinsic mechanisms account for changes 
in the central and peripheral T compartments 
found in CD6-deficient mice
To determine whether the defect in developing and mature 
lymphocytes observed in CD6−/− mice is T cell–intrinsic, 
competitive mixed BM chimera experiments were per-
Figure 1. Abnormal thymocyte maturation in CD6−/− mice. (A) Schematic representation of the gene targeting strategy used for generating CD6−/− 
mice. (B) Flow cytometry analysis of CD3+CD19− LN T cells from CD6+/+ (solid line), CD6+/− (dashed line), and CD6−/− (gray shaded line) mice stained for 
CD6 expression (mAb OX-129) or unstained as control (FMO, dotted line). (C) Total cell numbers in thymi (left) from CD6+/+ (open circles) and CD6−/− (gray 
filled circles) mice. The percentage (mean ± SEM) of main thymocyte subsets (middle) and of immature (TCRβ−CD24+) and mature (TCRβ+CD24−) CD8+ 
cells (right) is also shown. (D) Contour plot showing CD69 and TCRβ expression on gated DP cells from a CD6+/+ mouse. Histograms show CD5 (top) and 
CD6 (bottom) expression on nonselected (CD69−TCRβlo; gray line), and positively selected (CD69+TCRβ+; black line) DP cells from CD6+/+ mice. (E, left) 
Representative contour plots showing the percentage of DP, CD4+ SP, and CD8+ SP cells among total live CD69+ thymocytes in CD6+/+ and CD6−/− mice. 
Percentage (mean ± SEM) of CD69+ cells in CD4+SP, CD8+SP, and DP subsets. Each dot represents an individual mouse. *, P < 0.05; **, P < 0.01; ***, P = 0.001 
(unpaired Student’s t test).
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formed. CD3-ε–deficient mice were used as recipients of 
BM cell mixes (1:1) from CD6+/+ (WT45.1) mice with that 
of CD6−/− (KO45.2) or CD6+/+ (WT45.2) mice (Fig. 3 A). 
Control mice injected with only CD6+/+ or CD6−/− BM cells 
showed no significant differences in total cell numbers from 
primary and secondary lymphoid organs (unpublished data), 
indicating that absence of CD6 did not affect BM engraftment 
and/or thymic seeding. In the mixed chimera control group 
(WT45.2/WT45.1), a competitive advantage for CD45.2 
cells was observed as visible by CD45.2/CD45.1 ratios >1 
(Fig. 3 B). However, this advantage was modulated in the ex-
perimental group (KO45.2/WT45.1), where the CD45.2/
CD45.1 ratio was substantially reduced. In the thymus, this 
effect was observed for all major thymocyte developmental 
subsets, though it reached statistical significance only for DN 
and CD4+SP and CD8+SP. This indicates that CD6−/− T cells 
present a competitive disadvantage from very early stages of 
their development in regard to their CD6+/+ counterparts. In 
the periphery, a significant reduction of CD6−/− SP CD4+ and 
CD8+ T cells was also apparent in LNs (Fig. 3 C) and spleen 
(not depicted). Importantly, such a disadvantage was restricted 
to T cells, as the percentage of CD6−/− CD45.2 B cells in both 
the LN (Fig. 3 C) and spleen (not depicted) was not affected 
as compared with the control group. Overall, these results in-
dicate that CD6 deficiency confers a selective disadvantage to 
developing T cells in a cell autonomous manner and that, in a 
competitive setting, the presence of peripheral CD6−/− T cells 
was also reduced. As observed in CD6−/− mice, (Fig. 2, D and 
Figure 2. Phenotypical changes in peripheral T cell compartments in CD6−/− mice. (A, left) Total cell numbers in LN and spleen from CD6+/+ (open 
circles) and CD6−/− (gray filled circles) mice. (right) Percentage (mean ± SEM) of CD19+ (B), and CD4+, and CD8+ (T) cells from spleen and LNs. Each dot 
represents an individual mouse. (B) Flow cytometry analysis of spleen T cell surface marker expression from CD6+/+ (black solid line), CD6+/− (black dashed 
line), and CD6−/− (gray shaded line) mice. (C) Flow cytometry analysis of CD5 (top) and CD6 (bottom) expression on CD4+ and CD8+ spleen T cells, and DN, 
DP, CD4+SP, and CD8+SP thymocytes from wild-type (black solid line) and deficient (gray shaded line) mice for CD6 (top) and CD5 (bottom) receptors. FMO 
(dotted line). (D, left) Representative contour plots showing the percentage of CD4+ TEM (CD44hi CD62Llo) and CD8+ TCM (CD44hi CD62Lhi) cells from spleen 
of CD6+/+ and CD6−/− mice. (right) Percentage (mean ± SEM) of CD4+ TEM and CD8+ TCM cells in spleen and LN from CD6+/+ (open circles) and CD6−/− (gray 
filled circles) mice. (E, left) Representative contour plots showing the frequency of CD25+FoxP3+ in gated CD4+ thymus and spleen cells from CD6+/+ (left) 
and CD6−/− (right) mice. (right) Percentage (mean ± SEM) of T reg cells (CD4+CD25+FoxP3+) in thymus, spleen, and LNs from CD6+/+ (open circles) and 
CD6−/− (gray filled circles) mice. (F, left) Representative flow cytometry histograms showing in vivo BrdU incorporation into CD8+TCM (top) and CD4+TEM 
(bottom) spleen cells from CD6+/+ (black solid line) and CD6−/− mice (gray shaded line). (right) Dot density graph showing percentage (mean ± SEM) of 
BrdU+ CD8+TCM and CD4+TEM cells in spleen and LN from CD6+/+ (open circles) and CD6−/− (gray filled circles) mice. *, P < 0.05; **, P < 0.01; ***, P < 0.001 
(unpaired Student’s t test).
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E), increased frequencies of CD6−/− T reg and CD8+TCM cells 
could be detected in peripheral lymphoid organs of KO45.2/
WT45.1 mixed-BM chimeras compared with their CD6+/+ 
counterparts from control WT45.2/WT45.1 mixed chime-
ras (Fig. 3 D), indicating that such phenotypic alterations are 
also T cell intrinsic.
CD6 sets the threshold for negative selection in the thymus
The aforementioned results suggest that CD6 deficiency al-
ters thymocyte selection by lowering the threshold for neg-
ative selection and decreasing the number of cells reaching 
the CD4+SP and CD8+SP stage. Considering that TCR 
repertoire readjustments may occur and complicate result 
interpretation in mice with polyclonal T cell populations, 
we further addressed the role of CD6 in intrathymic T cell 
section using CD6−/− mice in which all T cells bear a single 
specific TCR. For that purpose, CD6−/− mice were crossed 
with either OT-I TCR mice, which produces MHC class 
I–restricted, OVA-specific CD8+ T cells, or with Marilyn 
mice, whose CD4+ cells are MHC class–II restricted for the 
male HY antigen. CD6−/− OT-I mice showed a reduction 
in the number of thymic CD8+SP cells expressing the TCR 
transgene, which reached statistical significance in periph-
eral organs (Fig. 4 A). Interestingly, CD6−/− OT-I mice also 
showed an increased proportion of peripheral CD8+ TCM 
cells (CD44hiCD62Lhi) compared with their CD6+/+ coun-
terparts (Fig. 4 B). In Marilyn mice, female CD6−/− showed 
a reduced number of thymic CD4+SP cells expressing the 
TCR transgene, which again reached statistical significance 
in spleen and LNs (Fig. 4 C). Collectively, these data indicate 
that CD6 regulates TCR signaling on developing and anti-
gen-experienced T cells.
This result is reminiscent of the well-acknowledged 
negative regulatory role of CD5 in T cell development and 
activation (Tarakhovsky et al., 1995). The CD5 receptor 
is closely related to CD6 both structurally and genetically 
(Soldevila et al., 2011) and its expression is developmentally 
regulated by TCR avidity, contributing to the fine tuning 
of TCR signaling (Azzam et al., 2001). Consequently, CD5 
surface levels on thymocytes and peripheral T cells parallel 
the avidity of their TCRs, as demonstrated by the higher 
levels of Nur-77 found in CD5hi peripheral T cells com-
pared with CD5lo (Fulton et al., 2015). Nur-77 levels are 
considered a sensitive readout of TCR signaling strength and 
are also found to be elevated in CD6hi peripheral T cells 
compared with CD6lo counterparts (Fig. 4 D), further sup-
porting the role of CD6 as a putative negative regulator under 
high-avidity TCR conditions.
Figure 3. Alterations in central and peripheral T cell compartments in the absence of CD6 are cell intrinsic. (A) Schematic representation of com-
petitive mixed BM chimeras experiment performed. (B) Dot density graph showing the ratio (mean ± SD) between the percentage of CD45.2+ and CD45.1+ 
cells in DN, DP, and SP subsets from control (WT45.2/WT45.1; open circles) and index (KO45.2/WT45.1; gray filled circles) experimental groups of mixed BM 
chimera assays. Each dot represents an individual mouse. (C) Dot density graph showing the ratio (mean ± SD) between the percentage of CD45.2+ and 
CD45.1+ cells in LN CD3+ CD4+ and CD8+ (left) and B220+ (right) cells from the same groups as in B. (D) Dot density graph showing the percent (mean ± 
SEM) of CD4+CD25+FoxP3+ T cells (left), CD8+TCM cells (middle), and CD4+TEM (right) gated on CD45.1 or CD45.2 cells from the KO45.2/WT45.1 group. *, P < 
0.05; **, P < 0.01; ***, P < 0.001 (unpaired Student’s t test).
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Influence of CD6 deficiency on TCR complex-induced 
responses from developing T cells
The fate of developing thymocytes is determined by the TCR 
signal strength resulting from interaction with MHC–self pep-
tide complexes presented by thymic APCs (Palmer, 2003). Such 
a signal is negatively modulated by CD5, and as a consequence 
CD5−/− T cells are hyperresponsive to TCR cross-linking 
(Tarakhovsky et al., 1995). The analysis of TCR-induced Ca2+ 
flux showed that CD6−/−, similar to CD5−/−, displayed higher 
intracellular [Ca2+] than CD6+/+ cells (Fig. 5 A). Further anal-
yses showed that CD6−/− DP, but not CD4+SP or CD8+SP, 
were responsible for the increased Ca2+ responses observed 
(Fig. 5 B). Consistent with this, no differences in Ca2+ responses 
were observed for spleen CD4+ or CD8+ T cells from CD6−/− 
and CD6+/+ mice (unpublished data). The increased Ca2+ 
responses observed in CD6−/− DP thymocytes could not be at-
tributed to the partial CD5 down-regulation observed in these 
cells, as Ca2+ fluxes from CD5+/− mice, which display similar 
CD5 surface levels to those observed in CD6−/− (Fig. 5 C, left), 
did not differ from those observed with CD6+/+ thymocytes 
(Fig. 5 C, right). Moreover, CD5+/− mice did not show other 
alterations found in CD6−/− mice, such as reduced frequency 
of thymic CD4+SP cells or increase of peripheral CD8+TCM 
cells (Fig. 5 D). Thus, the phenotype observed for CD6−/− 
mice, in terms of Ca2+ flux, decrease in thymocyte maturation 
and increase of memory phenotype in the periphery, is caused 
by CD6 deficiency and not to the reduced expression of CD5.
Increased peripheral CD4+ proliferative responses, low T 
reg cell suppressive activity, and exacerbated autoimmune 
response in CD6−/− mice
Overall, Ca2+ measurements indicate that CD6 behaves as a 
negative regulator of TCR signaling in immature (DP) but not 
mature (SP) thymocytes nor peripheral T cells. However, in 
vitro CD3-mediated stimulation of CD6−/− CD4+ and CD8+ 
peripheral T cells resulted in slightly increased proliferative 
responses, which reached statistical significance for CD4+ 
cells (Fig. 6 A) but disappeared under CD28 co-stimulatory 
conditions. In contrast, CD5−/− T cells, used for comparative 
purposes, showed significantly higher proliferative responses 
under both stimulatory conditions (Fig. 6 A). This indicates 
that, under ligand-independent conditions, CD6 has the ca-
pacity of negatively regulating T cell activation. However, 
it should be mentioned that under ligand-dependent con-
ditions (e.g., MLR) the missing CD6–ALC AM interaction 
could result in suboptimal cell–cell contacts and net lower 
proliferative responses of CD6−/− T cells (unpublished data).
The increased proportion of peripheral T reg cells led 
us to assess their functional status. As shown in Fig.  6  B, 
CD6−/− spleen CD4+CD25+ T cells exhibited lower suppres-
sive activity in vitro compared with CD6+/+ counterparts, 
indicating that CD6 expression is required for full T reg cell 
functionality. These results are in agreement with the fact that 
T reg cell function has been linked to correct SLP-76–me-
diated signaling (Schmidt et al., 2015), and that CD6 consti-
Figure 4. Effect of CD6 deficiency on SP subsets from TCR transgenic mice. (A, left) Representative contour plots indicating the percentage of CD8+ 
SP cells from CD6+/+ and CD6−/− OT-I TCR transgenic mice. (right) Total CD8+TCRα-2+ cell numbers (mean ± SEM) in thymus, spleen, and LNs from CD6+/+ 
(open bars) and CD6−/− (gray filled bars) OT-I mice (n = 4 for each genotype). (B) Representative contour plots showing CD44 and CD62L staining of gated 
LN CD8+ from CD6+/+ (top) and CD6−/− (bottom) OT-I mice. Percentage of SP and DP cells are indicated. (C, left) Representative contour plots showing the 
percentage of CD4+ SP cells from male CD6+/+ or CD6−/− Marilyn mice. (right) Total numbers of CD4+TCRβ-6+ cells (mean ± SEM) in thymus, spleen and LN 
from male CD6+/+ (open bars) or CD6−/− (gray filled bars) Marilyn mice (n = 4 for each genotype). (D) Analysis of Nur-77 expression in CD6hi and CD6lo pe-
ripheral T cells. LN cell suspensions from WT C57BL/6 mice were surface stained for CD4, CD8, CD5, and CD6, and then intracellularly for Nur-77. (top) FACS 
histograms showing CD6 (left) and CD5 (right) expression on pregated CD8+ cells. (bottom) FACS analysis of Nur-77 expression on gated cells representing 
the 5–6% with the highest (hi, black solid line) and lowest (lo, black dotted line) positivity for CD6 (left) and CD5 (right) expression in CD8+ T cells. FMO (gray 
shaded line), cells unstained for Nur-77. *, P < 0.05; **, P < 0.01 (unpaired Student’s t test).
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tutes a key element of the SLP-76 interactome (Roncagalli 
et al., 2014). Thus, CD6 deficiency would prevent T reg cells 
from proper recruitment of SLP-76, an essential signaling ef-
fector for their function.
To further explore the possibility that CD6 deficiency 
may result in dysregulated immune responses to auto-anti-
gens in vivo as a consequence of defective T reg cell function 
and/or defective modulation of TCR signaling, we evaluated 
the susceptibility of CD6−/− mice to CIA, a well-established 
model of T cell–mediated autoimmune disease resembling 
rheumatoid arthritis. As illustrated by Fig. 6 C, CD6−/− mice 
showed an earlier CIA onset and a significantly increased 
CIA incidence and clinical score than their CD6+/+ litter-
mates. This exacerbated CIA form was accompanied by 
a significantly enhanced joint expression of TNF and IL-6 
transcripts and a reduced expression of FoxP3 (Fig. 6 D). In-
creased expression of IL-17A and IL-1β transcripts were also 
observed, but these differences did not reach statistical sig-
nificance (Fig. 6 D). No differences regarding IFN-γ, IL-10, 
and TGF-β transcript levels were found (unpublished data). 
These results are compatible with CD6 deficiency potenti-
ating an induced Th17 autoimmune response to collagen in 
the context of a dysfunctional T reg cell activity. This is par-
ticularly relevant in the light of a study correlating polymor-
phisms in the human CD6 gene with susceptibility to certain 
autoimmune diseases, such as rheumatoid arthritis or mul-
tiple sclerosis (Kofler et al., 2016). Although the functional 
consequences of CD6 polymorphism associated to rheuma-
toid arthritis has not been analyzed, carriers of the multiple 
sclerosis risk allele (rs17828933GG) show altered CD4+ T cell 
responses and changes in the proportion of full-length and 
CD6ΔD3 isoforms in both CD4+ and CD8+ cells (Kofler 
et al., 2016), but their consequences on disease susceptibil-
ity merit further study.
Concluding remarks
This study represents the first in vivo characterization of CD6 
deficiency. The results show that CD6 acts as a negative mod-
ulator of TCR-mediated signaling, setting the threshold for 
the final steps of T cell selection and maturation, and likely 
for peripheral T cell activation. The molecular mechanisms 
by which CD6 restrains TCR signaling are speculative, as 
Figure 5. Modulation of TCR-induced responses from CD6−/− developing and mature T cells. (A, left) Fluorescence microscopy assessment of SOCE 
over time in Fura-2 AM–loaded thymocytes from CD6+/+ (n = 199 cells, open circles), CD6−/− (n = 188 cells, gray filled circles), and CD5−/− (n = 198 cells, black 
filled circles) mice after exposure to 145.2C11 mAb (αCD3) and Fc-specific antiserum (αIgG; n = 4 mice/genotype). (right) SOCE as represented by mean ± 
SEM of area under curve (AUC) from the same experiment. (B) FACS analysis of i[Ca2+] over time in Indo-1 AM–loaded DP, CD8+SP, and CD4+SP cells from 
CD6+/+ (black solid line) and CD6−/− (gray solid line) mice exposed to biotinylated 145.2C11 mAb (αCD3) plus Streptavidin (SAv). Data are representative of 
three independent experiments. (C, left) FACS analysis of CD5 expression on DP thymocytes from CD6+/+ (black solid line), CD5+/− (black dashed line), and 
CD6−/− (gray shaded line). (right) FACS analysis of i[Ca2+] over time of Indo-1 AM–loaded DP cells from CD6+/+ (black solid line), CD5+/− (black dashed line), 
CD6−/− (gray solid line) and CD5−/− (gray dashed line) mice, upon exposure to αCD3 mAb plus SAv, as assessed in B. (D) Dot density graphs showing the 
percentage (mean ± SEM) of major thymocyte subsets (left) and of LN CD4+ and CD8+ TEM and TCM subsets (right) from CD5+/− (black filled circles), CD6+/+ 
(open circles), and CD6−/− (gray filled circles) mice. The results shown are from one representative of two experiments performed. **, P < 0.01; ***, P < 0.001 
(unpaired Student’s t test).
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CD6 signaling pathway is still relatively unknown. Given the 
reported association of CD5 and CD6 at the T cell surface 
(Gimferrer et al., 2003) and the regulatory role of CD6 on 
CD5 Tyr phosphorylation (Castro et al., 2003), CD5 could 
mediate such a negative effect. This situation would be anal-
ogous to that reported for CD2, which transduces inhibitory 
signals through its association with CD5 (Teh et al., 1997; 
Castro et al., 2002). Alternatively, CD6 could directly recruit 
downstream negative signaling effectors (e.g., protein Tyr 
phosphatases). The possibility that, apart from decreasing the 
threshold for negative selection, the absence of CD6 impacts 
thymocyte selection in other manners cannot be excluded. 
Indeed, CD6 has been related to resistance to apoptosis in 
different experimental settings. Accordingly, CD6 is up-reg-
ulated both in DP cells undergoing positive selection and 
thymocytes resistant to in vitro induced-apoptosis (Singer 
et al., 2002), and CD6 ligation protects chronic lymphocytic 
leukemia cells from IgM-induced apoptosis (Osorio et al., 
1997). Moreover, CD6 expression protects leukemic T cells 
from galectin-induced apoptosis (Escoda-Ferran et al., 2014). 
Thus, further investigation into the role of CD6 as a pro-sur-
vival protein is required.
The CD6–ALC AM interaction is certainly a relevant 
driver of the observed effects on T cell development and pe-
ripheral T cell homeostasis. However, it has been observed 
that interactions between developing thymocytes (CD6+) and 
TECs (ALC AM+) are not sustained by long-term synapses, but 
rather by transient and repeated contacts with different TECs 
that maintain NFAT transcription and allow positive selection 
(Ebert et al., 2008). According to this model, the CD6–ALC 
AM interaction might be somewhat dispensable in the thy-
mus, where the negative role of CD6 would be more evident.
The generation and maintenance of antigen-experi-
enced T cells, such as CD4+TEM, CD8+TCM, and T reg cells, 
in CD6−/− mice has been linked to a certain level of TCR 
signal strength and/or co-stimulation (Lanzavecchia and Sal-
lusto, 2005). This fits with the view of CD6 as a negative 
regulator of thymic and peripheral TCR-mediated signaling. 
Indeed, absence of CD6 led to increased negative selection in 
the thymus and increased activation in response to self- or en-
vironmental antigens in the periphery, as shown by expansion 
of T cell subsets with memory and regulatory phenotypes. 
These data are reminiscent of those obtained from the anal-
ysis of CD5−/− mice, where expansion of both memory and 
regulatory (Ordoñez-Rueda et al., 2009) T cells are also ob-
Figure 6. Effect of CD6 deficiency on peripheral T cell proliferative 
responses, T reg cell activity, and CIA. (A) Proliferative responses of 
CFSE-labeled CD4+ and CD8+ T cells isolated from spleen and LN of CD6+/+ 
(open circles; n = 4–7 mice/point), CD6−/− (gray filled circles; n = 4–7 mice/
point), and CD5−/− (black filled circles; n = 3 mice/point) cultured for 72 h 
in the presence of different concentrations of plastic-bound anti-CD3 mAb 
alone (top) or plus soluble anti-CD28 mAb (bottom; 1 µg/ml). Shown is the 
percentage (mean ± SEM) of CFSElo in CD4+ and CD8+ cells. **, P < 0.01 
(Two-way ANO VA test). Data are cumulative results from four different ex-
periments. (B, top) Gating strategy used to electronically sort regulatory (T 
reg, CD4+CD25+) and conventional (T conv, CD4+CD25−) spleen T cells from 
CD6−/− or CD6+/+ mice. (bottom) CFSE-stained T conv cells from CD6+/+ 
mice were cultured in anti-CD3–coated plates plus soluble anti-CD28 mAb 
(1 µg/ml) in the absence (w/o) or presence of T reg cells from CD6−/− or 
CD6+/+ mice at different ratios. The percentage of CFSElo lymphocytes at 
day 3 of culture from one experiment of four performed is shown. *, P < 
0.05 (unpaired Student’s t test). (C, left) Clinical severity (mean ± SEM) 
at different weeks after CIA induction. (right) Cumulative incidence (per-
centage of affected mice) at the indicated weeks after CIA. **, P < 0.01; ***, 
P < 0.001 (two-way ANO VA test, followed by Bonferroni post-tests). (D) 
Quantitative RT-PCR analysis of joint mRNA levels (mean ± SD fold change 
of triplicates) of IL-6, TNF, FoxP3, IL-1β, IL-17A, and IFN-γ relative to GAP 
DH expression, before (NI, n = 3) and 8 wk after CIA of CD6+/+ (n = 8) and 
CD6−/− (n = 5) mice. *, P < 0.05 (Student’s t test).
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served. Thymic generation of T reg cells requires high-avid-
ity interaction of TCR with self-peptide–MHC complexes. 
Accordingly, increased frequency of T reg cells in thymus and 
periphery were previously reported for CD5−/− mice, the 
suppressive functionality of which is debatable (Dasu et al., 
2008; Ordoñez-Rueda et al., 2009). However, although in-
creased proportions of T reg cells can be seen in thymus and 
periphery of CD5−/− mice, they could only be detected in 
peripheral lymphoid organs of CD6−/− mice. This would in-
dicate that CD6 is particularly relevant for regulating the gen-
eration of extrathymic T reg cells during immune responses, 
rather than during thymic T cell selection. Furthermore, 
the ex vivo analysis of CD6−/− spleen T reg cells showed a 
lower suppressive activity, further indicating that CD6 is also 
relevant to T reg cell functionality. The in vivo biological 
meaning of our findings is supported by the fact that CD6−/− 
mice present an exacerbated form of an inducible autoim-
mune disease model (CIA).
Thus, the CD6-deficient mice described here represent 
a new and useful tool to fully understand the multifaceted 
mechanisms by which CD6 exerts its regulatory functions in 
different physiological and pathological contexts. Importantly, 
these mice can also provide valuable insights for the CD6-
based therapies that are currently under assessment for clin-
ically relevant diseases such as psoriasis, rheumatoid arthritis, 
or lymphoproliferative disorders (Hernández et al., 2016).
MAT ERI ALS AND MET HODS
Mice. CD6-deficient mice were generated in C57BL/6N 
background as previously described (Skarnes et al., 2011) 
through the Mouse Biology Program (University of Califor-
nia, Davis, Davis, CA) using targeting vector DPGS00142_B_
G12 from the trans-NIH Knock-Out Mouse Project 
(KOMP), and obtained from the KOMP Repository. The 
gene-targeting vector was designed to delete exons 3–6 from 
the cd6 gene coding for the three SRCR extracellular do-
mains and the stalk region. It was successfully used to obtain 
a recombinant ES cell clone (JM8A1.N3) that gave rise to 
chimerical mice after injection into pseudo-pregnant female 
mice. After germ-line transmission of the mutant allele, de-
noted as C57BL/6N-Atm1Brd, a homozygous (CD6−/−) colony 
was established. Absence of CD6 protein expression on T cells 
was confirmed by flow cytometry. The CD6−/− mice were 
viable and fertile, and their lifespans and behaviors were 
equivalent to their WT littermates. CD5-deficient mice 
(Tarakhovsky et al., 1995) on C57BL/6 background were 
provided by C. Raman (University of Alabama, Birmingham, 
AL). Mice were maintained at the animal facilities of the Uni-
versitat de Barcelona School of Medicine (Barcelona, Spain) 
under specific pathogen–free conditions.
CD6−/− and CD6+/+ mice were bred with MHC class 
I–restricted, OVA-specific OT-I (Clarke et al., 2000) and 
MHC class II–restricted male HY-specific Marilyn (Scott 
et al., 2000) TCR-transgenic lines at the Centre d’Immu-
nologie Marseille-Luminy (CIML; Marseille, France) and 
maintained in SPF conditions. CD3ε-deficient (CD3εΔ5/Δ5) 
mice displaying thymocyte development arrest at DN3 stage 
(Malissen et al., 1995) used as hosts in BM chimera exper-
iments were also kept at CIML. All the experiments were 
carried out in accordance with the guidelines of the Comité 
Étic d’Experimentació Animal from Universitat de Bar-
celona. Sex- and age-matched (8–12 wk) mice were used 
in all the experiments.
Calcium-flux measurement. Cytosolic Ca2+ signal was deter-
mined by two different approaches. In the case of fluores-
cence microscopy assessment of TCR-induced store operated 
calcium release (SOCE) over time, cells were loaded with 
4.5 µM Fura-2 AM (30 min) as previously described (Carre-
ras-Sureda et al., 2013). Cytosolic [Ca2+] increases are pre-
sented as the ratio of emitted fluorescence (510 nm) after 
excitation at 340 and 380 nm, relative to the ratio measured 
before cell stimulation (Fura-2 AM ratio 340/380). All exper-
iments were performed at room temperature, and cells were 
bathed in a solution containing 140 mM NaCl, 5 mM KCl, 
1.2  mM CaCl2, 0.5  mM MgCl2, 5  mM glucose, 10  mM 
Hepes (300 mosmol/l, pH 7.4). Ca2+ entry was achieved 
using 1 µg/ml of anti-CD3ε mAb (145.2C11; BD), and 
cross-linking was performed using goat anti–Armenian ham-
ster IgG (MP Bio). In the case of flow cytometry analysis, 
thymus and spleen cells were loaded for 20 min at 37°C with 
Indo-1 AM (Molecular Probes), and then stained with fluo-
rescent-labeled anti-CD4 (RM4-5, PE; BD) and anti-CD8 
(53–6.7, APC; BD). Basal fluorescence was recorded with an 
LSR II-UV (BD) before addition of 2.5 µg biotinylated an-
ti-CD3 (145.2C11; BD). Cross-linking of anti-CD3 mAb 
was induced by the addition of streptavidin (10 µg/ml; 
Thermo Fisher scientific). Calcium fluxes were determined 
on gated CD4+ and CD8+ cells. As loading control, cells were 
stimulated with Ionomycin (1 µg/ml; Sigma-Aldrich).
FACS analyses. Cell staining was done with fluorescently la-
beled mAbs to CD5 (53–7.3), CD4 (RM4-5), CD8α (53–
6.7), CD24 (M1/69), TCR-Vα2 (B20.1TCR-Vβ6 (RR4-7), 
TCRγ (GL-3), and TCRβ (H57-597) were purchased from 
BD; CD62L (MEL-14), CD44 (IM7), CD69 (H1.2F3), CD3 
(145.2C11), and FoxP3 (3G3) were obtained from TON BO 
Bioscience; CD25 (PC61.5), CD19 (6D5), CD161 (PK136), 
and CD6 (OX129) were purchased from BioLegend; and 
Nur77 (12.14) was obtained from eBioscience; all were used 
according to the manufacturer’s instructions. FACS analy-
ses were done on a LSR II 564 or FACS Canto II system 
(BD) using FlowJo software (TreeStar). Cell viability was 
evaluated either with SYT OX Blue (Life Technologies) or 
633- or 405-nm Viability dyes (Life Technologies). Apoptotic 
cells were detected by using Annexin V-FITC apoptosis de-
tection kit (Immunostep).
Mixed BM chimeras. Before use, 8-wk-old CD3εΔ5/Δ5 recipi-
ent mice received one single dose of irradiation (300 rads) to 
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eliminate partially endogenous immune cells and to allow ef-
ficient engraftment. Mice were then injected i.v. with 2 × 106 
BM cells from CD6+/+ (CD45.1) and from CD6−/− (CD45.2) 
mice, to generate mixed chimeras. As control groups, recipi-
ent CD3εΔ5/Δ5 mice (CD45.2) were injected with 4 × 106 
BM cells from either CD6+/+ or CD6−/− mice. Mouse chi-
meras were kept on antibiotic-containing water (0.2% Bac-
trim; Roche) during the whole experiment and euthanized at 
12 wk for FACS analyses on gated CD3+ or B220+ lymphocytes.
In vivo BrdU incorporation assay. For the detection of prolif-
erating cells in vivo, CD6−/− and CD6+/+ littermate mice 
were administered for 1 wk with BrdU (0.8 mg) into drink-
ing water, changing water every 2 d. BrdU+ cells were visual-
ized by FACS with BrdU Cell Proliferation Assay kit (BD) 
following the manufacturer’s instructions.
In vitro T cell proliferation and T reg cell suppression assay. 
CD4+ and CD8+ T cells were negatively isolated from spleen 
and LN (Dynabeads; Life Technologies) and incubated for 15 
min with CellTrace CFSE Cell Proliferation kit (Life Tech-
nologies), and then cultured in complete RPMI medium 
(10% FCS, 10 mM Hepes, 1 mM sodium pyruvate, 50 µM 
β-Mercaptoethanol, and 5 mM Penicillin-Glutamine-Strep-
tomycin; Lonza) in 96-well plates coated with increas-
ing concentrations of purified anti-CD3 mAb (145.2C11; 
TON BO Bioscience) alone or in combination with 1 µg/
ml soluble anti-CD28 mAb (37.51; TON BO Bioscience) 
for 72 h at 37°C, 5% CO2.
For T reg cell suppression assays, CD4+CD25− (T conv 
cells) and CD4+CD25+ (T reg cells) T cells were electroni-
cally sorted from spleen specimens and, upon CFSE-labeling 
of the former, co-cultured for 3 d at different ratios in 96-well 
plates coated with anti-CD3 mAb plus soluble anti-CD28. 
Proliferative responses were analyzed by determining the per-
centage of CFSElo cells by FACS.
CIA. Induction and assessment of CIA was done in 8–12-wk-
old male mice, as previously described (Postigo et al., 2011). 
In brief, mice were immunized once at the base of the tail 
with 150 µg of chicken collagen type II dissolved at a con-
centration of 2 mg/ml in 0.05 M acetic acid and emulsified 
with CFA containing 4 mg/ml of Mycobacterium tubercu-
losis in a final volume of 150 µl. Evaluation of arthritis clinical 
severity was performed weekly according to a graded scale of 
0–3 as follows: 0, no inflammation (normal joint); 1, detect-
able local swelling and/or erythema; 2, swelling in >1 joint 
and pronounced inflammation; 3, swelling of the entire paw 
and/or ankylosis. Each paw was graded, and the scores were 
summed (with a maximum possible score 12 per mouse). The 
expression of arthritogenic cytokines and FoxP3 in the joints 
was explored before and 8 wk after CIA induction by quan-
titative real time-PCR, as described previously (Postigo et al., 
2011). Results (in triplicate) were normalized to GAP DH 
expression and measured in parallel in each sample.
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